Breast Cancer During Pregnancy Maternal and Fetal Outcomes

被引:137
|
作者
Cardonick, Elyce [2 ]
Dougherty, Rebecca [1 ]
Grana, Generosa [3 ]
Gilmandyar, Dzhamlaa [4 ]
Ghaffar, Sadia [5 ]
Usmani, Aniqa [6 ]
机构
[1] Lankenau Hosp, Dept Internal Med, Acad Hospitalist Program, Wynnewood, PA 19096 USA
[2] Univ Med & Dent New Jersey, Cooper Univ Hosp, Dept Obstet & Gynecol, Camden, NJ USA
[3] Univ Med & Dent New Jersey, Cooper Univ Hosp, Dept Hematol & Oncol, Camden, NJ USA
[4] Long Isl Jewish, New Hyde Pk, NY USA
[5] Bergen Reg Med Ctr, Paramus, NJ USA
[6] Robert Wood Johnson, New Brunswick, NJ USA
来源
CANCER JOURNAL | 2010年 / 16卷 / 01期
关键词
pregnancy; breast cancer; chemotherapy; children; CARCINOMA; CHEMOTHERAPY;
D O I
10.1097/PPO.0b013e3181ce46f9
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Breast cancer is the most common malignancy occurring during pregnancy. Because more women delay childbearing, the diagnosis of cancer during pregnancy will likely increase. Case reports exist in the literature regarding the treatment of pregnant women with breast cancer, but few are prospective and few provide long-term follow-up on the neonate exposed to chemotherapy. In this report, 130 women diagnosed with breast cancer were reported to our voluntary national registry and followed up prospectively. Patient and Methods: The Cancer and Pregnancy Registry is a voluntary registry that monitors the clinical course, treatment, and disease outcome of women diagnosed with cancer during pregnancy and the perinatal and neonatal outcomes of their children. Results: Of the 130 diagnosed, 120 were diagnosed with a primary tumor, 8 with a recurrence, and 2 with a new primary cancer. Mean maternal age at diagnosis was 34.8 +/- 4.2 years. Mean gestational age at diagnosis was 13.2 +/- 8.1weeks. Gestational age was 12.8 +/- 7.8 weeks for patients with primary disease and 16.25 +/- 11 weeks for those with recurrent cancer. One hundred thirteen women were followed up for mean of 3.14 +/- 2.5 years. Of those followed up, 103 were diagnosed with primary breast cancer during pregnancy, 8 with a recurrence, and 2 with a new primary. Recurrence was reported in 30 patients at an average of 16.2 +/- 10.8 months from delivery to recurrence. Twenty-one patients are deceased with an average of 24.71 +/- 15.32 months from delivery to death. Only 42% were diagnosed with an estrogen-positive tumor and 35% of cases had a progesterone receptor-positive tumor. Human epidermal growth factor receptor 2 was positive in 25% of patients. Chemotherapy was given during pregnancy in 104 cases; the first treatment was given at a mean gestational age of 20.4 +/- 5.4 weeks. The malformation rate of exposed neonates was 3 not greater than the general population. Survival by stage for a primary diagnosis in pregnancy is as follows: stage I, 100%; stage II, 86%; stage III, 86%; and stage IV, 0%. Discussion: Pregnant women diagnosed with breast cancer can receive treatment comparable with nonpregnant women leading to a similar survival when matched for stage at diagnosis. The majority of children who were exposed to chemotherapy in utero did not demonstrate significant complications. We report the single largest cohort of women diagnosed with breast cancer during pregnancy.
引用
收藏
页码:76 / 82
页数:7
相关论文
共 50 条
  • [1] Breast cancer during pregnancy: Maternal and fetal outcomes
    Gilmandyar, D
    Robinson, D
    Cardonick, E
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2005, 193 (06) : S83 - S83
  • [2] Cancer in pregnancy: maternal and fetal outcomes
    Accurti, Veronica
    Carignani, Beatrice De Luca
    Grossi, Elena
    Loreto, Eugenia Di
    Matozzo, Cristina Maria Michela
    Castellani, Carlotta
    Cameli, Beatrice Ornella
    Fumagalli, Monica
    Polverino, Gianpiero
    Peccatori, Fedro Alessandro
    Scarfone, Giovanna
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2024, 34 (SUPPL_1) : A248 - A249
  • [3] Breast Carcinogenesis during Pregnancy: Molecular Mechanisms, Maternal and Fetal Adverse Outcomes
    Margioula-Siarkou, Georgia
    Margioula-Siarkou, Chrysoula
    Petousis, Stamatios
    Vavoulidis, Eleftherios
    Margaritis, Kosmas
    Almperis, Aristarchos
    Haitoglou, Costas
    Mavromatidis, George
    Dinas, Konstantinos
    BIOLOGY-BASEL, 2023, 12 (03):
  • [4] Maternal and fetal outcomes of taxane chemotherapy in breast and ovarian cancer during pregnancy: case series and review of the literature
    Cardonick, E.
    Bhat, A.
    Gilmandyar, D.
    Somer, R.
    ANNALS OF ONCOLOGY, 2012, 23 (12) : 3016 - 3023
  • [5] Hyperthyroidism during pregnancy: maternal-fetal outcomes
    Pinheiro, Amanda Tavares
    Araujo Costa, Roberto Antonio
    Abbade, Joelcio Francisco
    Magalhaes, Claudia Garcia
    Ferreira da Silva Mazeto, Glaucia Maria
    REVISTA BRASILEIRA DE GINECOLOGIA E OBSTETRICIA, 2008, 30 (09): : 452 - 458
  • [6] Antihypertensive treatment during pregnancy and maternal and fetal outcomes
    Vaclavik, J.
    Ramik, Z.
    Jarkovsky, J.
    Zouharova, A.
    Pohlova, R.
    Jirova, J.
    EUROPEAN HEART JOURNAL, 2024, 45
  • [7] Lone hyperuricemia during pregnancy: Maternal and fetal outcomes
    Merviel, P
    Ba, R
    Beaufils, M
    Breart, G
    Salat-Baroux, J
    Uzan, S
    EUROPEAN JOURNAL OF OBSTETRICS GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 1998, 77 (02): : 145 - 150
  • [8] MATERNAL AND FETAL OUTCOMES OF DENGUE INFECTION DURING PREGNANCY
    Tiawilai, Anongrat
    Trongkamolchai, Supachoke
    Khamim, Kriangsak
    Thisyakorn, Usa
    SOUTHEAST ASIAN JOURNAL OF TROPICAL MEDICINE AND PUBLIC HEALTH, 2017, 48 : 139 - 142
  • [9] Maternal factors during pregnancy influencing maternal, fetal, and childhood outcomes
    Muglia, Louis J.
    Benhalima, Katrien
    Tong, Stephen
    Ozanne, Susan
    BMC MEDICINE, 2022, 20 (01)
  • [10] Maternal factors during pregnancy influencing maternal, fetal, and childhood outcomes
    Louis J. Muglia
    Katrien Benhalima
    Stephen Tong
    Susan Ozanne
    BMC Medicine, 20